By Tami Luhby, NCS
(NCS) — Battling to regain its market share over rival Eli Lilly, Novo Nordisk introduced Tuesday that it’s going to cut back the list prices of its standard weight reduction drug Wegovy and diabetes medication Ozempic and Rybelsus by up to half beginning in 2027.
The $675 month-to-month list worth is geared toward making the GLP-1 drugs extra accessible for sufferers whose prices are linked to the list worth, together with those that have excessive deductibles or who pay co-insurance for drugs by their job-based plans.
Wegovy’s list worth is presently $1,349 and Ozempic’s and Rybelsus’ list prices are $1,028, however these with insurance coverage protection pays as little as $25 a month.
The transfer is the most recent within the GLP-1 worth wars between Novo Nordisk and Eli Lilly, which manufactures the load loss drug Zepbound and diabetes drug Mounjaro. Both firms are searching for to seize extra of the hovering demand for weight problems drugs and have been decreasing their prices for these prepared to pay money and forgo insurance coverage. Both have additionally signed “Most Favored Nation” offers with the Trump administration, which included giving them expanded entry to Medicare sufferers.
The list worth change doesn’t have an effect on the self-pay prices, the Danish drugmaker mentioned.
Prices for Wegovy tablets by direct-to-consumer channels vary from $149 to $299 a month, relying on dosage, whereas the Wegovy injectable pen prices $349 a month, with a reduced $199 worth accessible for new sufferers for the primary two months.
The Ozempic injectable pen prices between $349 and $499 a month, relying on dosage, with new self-pay sufferers paying $199 for the primary two months.
The Wall Street Journal first reported the list worth reductions.
Once the chief in GLP-1 drugs, Novo Nordisk has misplaced floor to Eli Lilly, which now captures extra new prescriptions for weight problems drugs. Novo Nordisk earlier this month forecast that its gross sales and revenue progress would decline this 12 months, sending its inventory worth plummeting. The firm on Monday revealed disappointing weight reduction leads to a trial for CagriSema, its next-generation weight problems drug.
The-NCS-Wire
™ & © 2026 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.